Sales Talent

FEBRUARY 7, 2020

**The 2022 Sales Hiring Forecast has been released – check it out now!**. It’s time for the 6th installment of our annual sales hiring forecast. As there isn’t a hiring forecast specific for b2b sales roles, we started our own forecast in 2015 to help fill this gap. 2019 Sales Hiring in Review. 2020 Sales Hiring Forecast.

Sales 52

Sales B2B Sales Recruitment Marketing 52

European Pharmaceutical Review

AUGUST 21, 2023

Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. GSK Furthermore, biopharma firm GSK reported +4 percent and +11 percent ex COVID sales in the second quarter of 2023. Drugs Verzenio, Jardiance and Taltz led this result.

Biopharma 98

Biopharma Marketing Sales Medicine 98

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2% million by 2029.

Marketing 52

Marketing Sales Pharma Leads 52

Every Ancillary

MAY 14, 2021

Most seasoned medical sales representatives have carried several different products or services over their careers. Between emerging technologies, expiring patents, and ever-changing insurance coverage, the role of a medical sales professional is to constantly adapt and learn new things. Selling cutting-edge technology is exciting.

Medical sales 52

Medical sales Medical Sales Insurance 52

pharmaphorum

AUGUST 4, 2022

The $52-per-share offer would give Amgen a drug that some analysts have described as a pipeline in a pill with $1 billion-plus sales potential, and is a sizeable premium on ChemoCentryx’ pre-deal announcement share price of just over $24. billion bid to buy out the company.

Side effects 83

Side effects Sales Pharma Competition 83

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

PM360

SEPTEMBER 21, 2023

They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

OCTOBER 10, 2022

Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies. .” “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients,” he added.

Sales 52

Sales FDA Pharma Competition 52

Clarivate

AUGUST 27, 2024

and ramped up sales of PFA systems in Europe. In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. s Farapulse.

Marketing 52

Marketing Competition FDA Electronics 52

Pharmaceutical Technology

OCTOBER 28, 2022

According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 billion and $812 million in 2028. VAX-24 has forecasted sales of $21 million in the same year. Competition in an increasingly heated market. Further plans in the making.

Training 64

Training Marketing Competition FDA 64

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Spotio

APRIL 4, 2023

billion by 2028. That means competition is fierce, especially in high-growth locations. Keep reading to learn 10 roofing sales tips you can use to drive more revenue in 2023. These 10 roofing sales tips will put you and your sales team in the best position to succeed. The industry grew by 2.7%

Prospecting 52

Prospecting Sales pitches Sales Leads 52

Pharmaceutical Technology

FEBRUARY 13, 2023

By this same virtue, PROTACs are able to degrade previously undruggable targets, which provides a major competitive advantage for this modality if shown to be true. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028.

Competition 59

Competition Safety Patients Pharmaceutical 59

PM360

SEPTEMBER 28, 2022

If government-negotiated discounts are not materially higher than rebates currently negotiated by payers, this could be comparable to passing through rebates at the point of sale, which could increase plan and government costs. In this type of class, selecting one product could materially disrupt competitive dynamics.

Government 97

Government Manufacturing Prescription Competition 97

Pharmaceutical Technology

APRIL 20, 2023

The district court had previously blocked Sandoz and Zydus from producing, selling, offering to sell, or importing generic versions of Otezla until February 2028. In 2022, Otezla made up for 9% of Amgen’s total product sales, having sold over $2.2 billion worth of the drug worldwide. 8, 093, 283 (the “’283 Patent”).

Competition 52

Competition Marketing FDA Prospecting 52